ENSG00000085224 |
ATRX |
brain glioblastoma |
frameshift_variant |
8.355% (130/1556) |
10 entries |
ENSG00000085224 |
ATRX |
pancreatic neuroendocrine tumor |
missense_variant |
13.44% (41/305) |
3 entries |
ENSG00000085224 |
ATRX |
brain astrocytoma |
stop_gained |
43.75% (21/48) |
1 entry |
ENSG00000085224 |
ATRX |
brain glioblastoma |
sequence_alteration |
8.355% (130/1556) |
5 entries |
ENSG00000085224 |
ATRX |
oligoastrocytoma |
sequence_alteration |
48.21% (27/56) |
3 entries |
ENSG00000085224 |
ATRX |
colon adenocarcinoma |
stop_gained |
8.34% (108/1295) |
2 entries |
ENSG00000085224 |
ATRX |
cecum adenocarcinoma |
sequence_alteration |
11.11% (30/270) |
1 entry |
ENSG00000085224 |
ATRX |
leiomyosarcoma |
frameshift_variant |
23.33% (28/120) |
3 entries |
ENSG00000085224 |
ATRX |
colon adenocarcinoma |
sequence_alteration |
8.34% (108/1295) |
3 entries |
ENSG00000085224 |
ATRX |
anaplastic oligoastrocytoma |
missense_variant |
46.99% (39/83) |
4 entries |
ENSG00000085224 |
ATRX |
oligoastrocytoma |
stop_gained |
48.21% (27/56) |
3 entries |
ENSG00000085224 |
ATRX |
pancreatic neuroendocrine tumor |
frameshift_variant |
13.44% (41/305) |
3 entries |
ENSG00000085224 |
ATRX |
colon adenocarcinoma |
frameshift_variant |
8.34% (108/1295) |
5 entries |
ENSG00000085224 |
ATRX |
pancreatic neuroendocrine tumor |
stop_gained |
13.44% (41/305) |
3 entries |
ENSG00000085224 |
ATRX |
oligoastrocytoma |
missense_variant |
48.21% (27/56) |
2 entries |
ENSG00000085224 |
ATRX |
glioma |
missense_variant |
12.2% (85/697) |
1 entry |
ENSG00000085224 |
ATRX |
glioma |
frameshift_variant |
12.2% (85/697) |
2 entries |
ENSG00000085224 |
ATRX |
glioma |
stop_gained |
12.2% (85/697) |
2 entries |
ENSG00000085224 |
ATRX |
breast ductal adenocarcinoma |
missense_variant |
9.948% (171/1719) |
2 entries |
ENSG00000085224 |
ATRX |
anaplastic astrocytoma |
sequence_alteration |
49.34% (112/227) |
3 entries |
ENSG00000085224 |
ATRX |
breast ductal adenocarcinoma |
stop_gained |
9.948% (171/1719) |
2 entries |
ENSG00000085224 |
ATRX |
brain glioblastoma |
missense_variant |
8.355% (130/1556) |
7 entries |
ENSG00000085224 |
ATRX |
anaplastic oligoastrocytoma |
stop_gained |
46.99% (39/83) |
4 entries |
ENSG00000085224 |
ATRX |
anaplastic astrocytoma |
frameshift_variant |
49.34% (112/227) |
7 entries |
ENSG00000085224 |
ATRX |
brain astrocytoma |
frameshift_variant |
43.75% (21/48) |
1 entry |
ENSG00000085224 |
ATRX |
cecum adenocarcinoma |
missense_variant |
11.11% (30/270) |
3 entries |
ENSG00000085224 |
ATRX |
HER2 Positive Breast Carcinoma |
missense_variant |
26.09% (36/138) |
1 entry |
ENSG00000085224 |
ATRX |
breast ductal adenocarcinoma |
sequence_alteration |
9.948% (171/1719) |
3 entries |
ENSG00000085224 |
ATRX |
oligoastrocytoma |
frameshift_variant |
48.21% (27/56) |
6 entries |
ENSG00000085224 |
ATRX |
pancreatic neuroendocrine tumor |
sequence_alteration |
13.44% (41/305) |
1 entry |
ENSG00000085224 |
ATRX |
brain glioblastoma |
stop_gained |
8.355% (130/1556) |
7 entries |
ENSG00000085224 |
ATRX |
cecum adenocarcinoma |
frameshift_variant |
11.11% (30/270) |
3 entries |
ENSG00000085224 |
ATRX |
leiomyosarcoma |
missense_variant |
23.33% (28/120) |
1 entry |
ENSG00000085224 |
ATRX |
HER2 Positive Breast Carcinoma |
sequence_alteration |
26.09% (36/138) |
1 entry |
ENSG00000085224 |
ATRX |
anaplastic oligoastrocytoma |
sequence_alteration |
46.99% (39/83) |
3 entries |
ENSG00000085224 |
ATRX |
glioma |
sequence_alteration |
12.2% (85/697) |
1 entry |
ENSG00000085224 |
ATRX |
leiomyosarcoma |
stop_gained |
23.33% (28/120) |
2 entries |
ENSG00000085224 |
ATRX |
colon adenocarcinoma |
missense_variant |
8.34% (108/1295) |
11 entries |
ENSG00000085224 |
ATRX |
colon adenocarcinoma |
conservative_inframe_deletion |
8.34% (108/1295) |
2 entries |
ENSG00000085224 |
ATRX |
anaplastic oligoastrocytoma |
frameshift_variant |
46.99% (39/83) |
6 entries |
ENSG00000085224 |
ATRX |
leiomyosarcoma |
sequence_alteration |
23.33% (28/120) |
1 entry |
ENSG00000085224 |
ATRX |
brain astrocytoma |
sequence_alteration |
43.75% (21/48) |
1 entry |
ENSG00000085224 |
ATRX |
anaplastic astrocytoma |
missense_variant |
49.34% (112/227) |
5 entries |
ENSG00000085224 |
ATRX |
anaplastic astrocytoma |
stop_gained |
49.34% (112/227) |
8 entries |
ENSG00000085224 |
ATRX |
acute myeloid leukemia |
stop_gained |
0.8624% (24/2783) |
1 entry |
ENSG00000085224 |
ATRX |
undifferentiated pleomorphic sarcoma |
stop_gained |
14.52% (9/62) |
1 entry |
ENSG00000085224 |
ATRX |
glioma |
amino_acid_insertion |
12.2% (85/697) |
1 entry |
ENSG00000085224 |
ATRX |
clear cell renal carcinoma |
missense_variant |
1.3% (21/1616) |
4 entries |
ENSG00000085224 |
ATRX |
Uterine Carcinosarcoma |
sequence_alteration |
8.485% (14/165) |
1 entry |
ENSG00000085224 |
ATRX |
Cortisol-Producing Adrenal Cortex Adenoma |
missense_variant |
1.613% (2/124) |
2 entries |
ENSG00000085224 |
ATRX |
skin melanoma |
stop_gained |
4.217% (49/1162) |
3 entries |
ENSG00000085224 |
ATRX |
papillary renal cell carcinoma |
missense_variant |
0.5155% (2/388) |
1 entry |
ENSG00000085224 |
ATRX |
lung adenocarcinoma |
sequence_alteration |
4.551% (117/2571) |
3 entries |
ENSG00000085224 |
ATRX |
Uterine Carcinosarcoma |
missense_variant |
8.485% (14/165) |
2 entries |
ENSG00000085224 |
ATRX |
adrenal gland pheochromocytoma |
missense_variant |
3.136% (9/287) |
2 entries |
ENSG00000085224 |
ATRX |
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
4.923% (32/650) |
2 entries |
ENSG00000085224 |
ATRX |
breast carcinoma |
frameshift_variant |
2.091% (35/1674) |
2 entries |
ENSG00000085224 |
ATRX |
Adrenal Gland Neuroblastoma |
missense_variant |
6.818% (6/88) |
1 entry |
ENSG00000085224 |
ATRX |
pancreatic neuroendocrine tumor |
conservative_inframe_deletion |
13.44% (41/305) |
1 entry |
ENSG00000085224 |
ATRX |
female breast carcinoma |
missense_variant |
3.767% (11/292) |
4 entries |
ENSG00000085224 |
ATRX |
hemangioblastoma |
missense_variant |
22.86% (8/35) |
1 entry |
ENSG00000085224 |
ATRX |
breast carcinoma |
conservative_inframe_deletion |
2.091% (35/1674) |
1 entry |
ENSG00000085224 |
ATRX |
lung adenocarcinoma |
frameshift_variant |
4.551% (117/2571) |
3 entries |
ENSG00000085224 |
ATRX |
hepatocellular carcinoma |
missense_variant |
1.763% (18/1021) |
2 entries |
ENSG00000085224 |
ATRX |
colorectal adenocarcinoma |
frameshift_variant |
6.924% (88/1271) |
2 entries |
ENSG00000085224 |
ATRX |
papillary thyroid carcinoma |
missense_variant |
1.174% (6/511) |
2 entries |
ENSG00000085224 |
ATRX |
breast carcinoma |
missense_variant |
2.091% (35/1674) |
3 entries |
ENSG00000085224 |
ATRX |
Adrenal Gland Neuroblastoma |
frameshift_variant |
6.818% (6/88) |
1 entry |
ENSG00000085224 |
ATRX |
lung adenocarcinoma |
stop_gained |
4.551% (117/2571) |
4 entries |
ENSG00000085224 |
ATRX |
Gallbladder Adenocarcinoma |
sequence_alteration |
5.455% (9/165) |
1 entry |
ENSG00000085224 |
ATRX |
Merkel cell skin cancer |
missense_variant |
4.211% (4/95) |
2 entries |
ENSG00000085224 |
ATRX |
small cell lung carcinoma |
sequence_alteration |
6.321% (28/443) |
2 entries |
ENSG00000085224 |
ATRX |
adrenal cortex carcinoma |
stop_gained |
3.67% (8/218) |
2 entries |
ENSG00000085224 |
ATRX |
basal cell carcinoma |
missense_variant |
14.71% (10/68) |
2 entries |
ENSG00000085224 |
ATRX |
astrocytoma |
missense_variant |
40.0% (6/15) |
2 entries |
ENSG00000085224 |
ATRX |
skin melanoma |
missense_variant |
4.217% (49/1162) |
5 entries |
ENSG00000085224 |
ATRX |
small cell lung carcinoma |
missense_variant |
6.321% (28/443) |
5 entries |
ENSG00000085224 |
ATRX |
melanoma |
missense_variant |
13.01% (19/146) |
3 entries |
ENSG00000085224 |
ATRX |
Cervical Small Cell Carcinoma |
missense_variant |
50.0% (4/8) |
1 entry |
ENSG00000085224 |
ATRX |
clear cell renal carcinoma |
sequence_alteration |
1.3% (21/1616) |
1 entry |
ENSG00000085224 |
ATRX |
mucosal melanoma |
frameshift_variant |
15.71% (11/70) |
1 entry |
ENSG00000085224 |
ATRX |
large cell lung carcinoma |
missense_variant |
10.53% (2/19) |
1 entry |
ENSG00000085224 |
ATRX |
nasopharyngeal squamous cell carcinoma |
frameshift_variant |
3.247% (10/308) |
1 entry |
ENSG00000085224 |
ATRX |
colorectal adenocarcinoma |
missense_variant |
6.924% (88/1271) |
4 entries |
ENSG00000085224 |
ATRX |
brain astrocytoma |
missense_variant |
43.75% (21/48) |
1 entry |
ENSG00000085224 |
ATRX |
esophageal adenocarcinoma |
missense_variant |
1.825% (10/548) |
2 entries |
ENSG00000085224 |
ATRX |
colon adenocarcinoma |
amino_acid_insertion |
8.34% (108/1295) |
1 entry |
ENSG00000085224 |
ATRX |
undifferentiated pleomorphic sarcoma |
frameshift_variant |
14.52% (9/62) |
1 entry |
ENSG00000085224 |
ATRX |
urothelial carcinoma |
missense_variant |
9.302% (8/86) |
1 entry |
ENSG00000085224 |
ATRX |
neoplasm |
missense_variant |
7.895% (3/38) |
1 entry |
ENSG00000085224 |
ATRX |
osteosarcoma |
stop_gained |
6.369% (10/157) |
3 entries |
ENSG00000085224 |
ATRX |
cecum adenocarcinoma |
conservative_inframe_deletion |
11.11% (30/270) |
1 entry |
ENSG00000085224 |
ATRX |
pleomorphic liposarcoma |
frameshift_variant |
44.44% (4/9) |
2 entries |
ENSG00000085224 |
ATRX |
non-small cell lung carcinoma |
missense_variant |
5.556% (6/108) |
2 entries |
ENSG00000085224 |
ATRX |
small cell lung carcinoma |
stop_gained |
6.321% (28/443) |
3 entries |
ENSG00000085224 |
ATRX |
chronic lymphocytic leukemia |
missense_variant |
4.372% (39/892) |
1 entry |
ENSG00000085224 |
ATRX |
brain glioblastoma |
amino_acid_insertion |
8.355% (130/1556) |
1 entry |
ENSG00000085224 |
ATRX |
Gallbladder Adenocarcinoma |
missense_variant |
5.455% (9/165) |
3 entries |
ENSG00000085224 |
ATRX |
bladder transitional cell carcinoma |
missense_variant |
3.68% (17/462) |
2 entries |
ENSG00000085224 |
ATRX |
squamous cell lung carcinoma |
sequence_alteration |
2.146% (20/932) |
1 entry |
ENSG00000085224 |
ATRX |
bladder transitional cell carcinoma |
frameshift_variant |
3.68% (17/462) |
1 entry |
ENSG00000085224 |
ATRX |
Brain Stem Glioblastoma |
missense_variant |
8.571% (6/70) |
2 entries |
ENSG00000085224 |
ATRX |
gastric adenocarcinoma |
missense_variant |
2.973% (25/841) |
5 entries |
ENSG00000085224 |
ATRX |
pancreatic ductal adenocarcinoma |
missense_variant |
6.306% (113/1792) |
3 entries |
ENSG00000085224 |
ATRX |
lobular breast carcinoma |
missense_variant |
5.435% (15/276) |
2 entries |
ENSG00000085224 |
ATRX |
myelodysplastic syndrome |
sequence_alteration |
3.515% (29/825) |
4 entries |
ENSG00000085224 |
ATRX |
prostate adenocarcinoma |
conservative_inframe_deletion |
3.614% (78/2158) |
1 entry |
ENSG00000085224 |
ATRX |
ulcerative colitis |
stop_gained |
44.44% (4/9) |
1 entry |
ENSG00000085224 |
ATRX |
oral squamous cell carcinoma |
missense_variant |
2.29% (6/262) |
4 entries |
ENSG00000085224 |
ATRX |
mucosal melanoma |
stop_gained |
15.71% (11/70) |
1 entry |
ENSG00000085224 |
ATRX |
basal cell carcinoma |
stop_gained |
14.71% (10/68) |
1 entry |
ENSG00000085224 |
ATRX |
Myelodysplastic/Myeloproliferative Neoplasm |
missense_variant |
20.0% (3/15) |
2 entries |
ENSG00000085224 |
ATRX |
prostate adenocarcinoma |
sequence_alteration |
3.614% (78/2158) |
1 entry |
ENSG00000085224 |
ATRX |
prostate carcinoma |
missense_variant |
1.549% (7/452) |
3 entries |
ENSG00000085224 |
ATRX |
Brain Stem Glioblastoma |
sequence_alteration |
8.571% (6/70) |
2 entries |
ENSG00000085224 |
ATRX |
nasopharyngeal squamous cell carcinoma |
missense_variant |
3.247% (10/308) |
3 entries |
ENSG00000085224 |
ATRX |
rectal adenocarcinoma |
frameshift_variant |
2.559% (14/547) |
1 entry |
ENSG00000085224 |
ATRX |
ovarian serous adenocarcinoma |
missense_variant |
0.949% (8/843) |
4 entries |
ENSG00000085224 |
ATRX |
colorectal adenocarcinoma |
conservative_inframe_deletion |
6.924% (88/1271) |
2 entries |
ENSG00000085224 |
ATRX |
brain glioma |
missense_variant |
13.95% (6/43) |
2 entries |
ENSG00000085224 |
ATRX |
prostate adenocarcinoma |
missense_variant |
3.614% (78/2158) |
3 entries |
ENSG00000085224 |
ATRX |
myelodysplastic syndrome |
stop_gained |
3.515% (29/825) |
2 entries |
ENSG00000085224 |
ATRX |
Endometrial Endometrioid Adenocarcinoma |
stop_gained |
4.923% (32/650) |
2 entries |
ENSG00000085224 |
ATRX |
mucosal melanoma |
amino_acid_insertion |
15.71% (11/70) |
1 entry |
ENSG00000085224 |
ATRX |
acute myeloid leukemia |
missense_variant |
0.8624% (24/2783) |
3 entries |
ENSG00000085224 |
ATRX |
brain astrocytoma |
conservative_inframe_deletion |
43.75% (21/48) |
1 entry |
ENSG00000085224 |
ATRX |
rectal adenocarcinoma |
missense_variant |
2.559% (14/547) |
3 entries |
ENSG00000085224 |
ATRX |
osteosarcoma |
missense_variant |
6.369% (10/157) |
2 entries |
ENSG00000085224 |
ATRX |
Kidney Angiomyolipoma |
frameshift_variant |
25.0% (2/8) |
1 entry |
ENSG00000085224 |
ATRX |
rectal adenocarcinoma |
stop_gained |
2.559% (14/547) |
1 entry |
ENSG00000085224 |
ATRX |
myelodysplastic syndrome |
missense_variant |
3.515% (29/825) |
5 entries |
ENSG00000085224 |
ATRX |
adrenal gland pheochromocytoma |
conservative_inframe_deletion |
3.136% (9/287) |
1 entry |
ENSG00000085224 |
ATRX |
gastric intestinal type adenocarcinoma |
missense_variant |
3.529% (3/85) |
2 entries |
ENSG00000085224 |
ATRX |
melanoma |
conservative_inframe_deletion |
13.01% (19/146) |
1 entry |
ENSG00000085224 |
ATRX |
squamous cell lung carcinoma |
missense_variant |
2.146% (20/932) |
1 entry |
ENSG00000085224 |
ATRX |
esophageal squamous cell carcinoma |
missense_variant |
1.887% (13/689) |
4 entries |
ENSG00000085224 |
ATRX |
diffuse large B-cell lymphoma |
missense_variant |
0.7143% (3/420) |
2 entries |
ENSG00000085224 |
ATRX |
osteosarcoma |
frameshift_variant |
6.369% (10/157) |
2 entries |
ENSG00000085224 |
ATRX |
Non-Functional Pancreatic Neuroendocrine Tumor |
missense_variant |
22.58% (7/31) |
1 entry |
ENSG00000085224 |
ATRX |
esophageal squamous cell carcinoma |
stop_gained |
1.887% (13/689) |
1 entry |
ENSG00000085224 |
ATRX |
anaplastic oligodendroglioma |
missense_variant |
3.974% (6/151) |
2 entries |
ENSG00000085224 |
ATRX |
colorectal adenocarcinoma |
stop_gained |
6.924% (88/1271) |
2 entries |
ENSG00000085224 |
ATRX |
hemangioblastoma |
sequence_alteration |
22.86% (8/35) |
1 entry |
ENSG00000085224 |
ATRX |
bladder carcinoma |
missense_variant |
3.922% (22/561) |
1 entry |
ENSG00000085224 |
ATRX |
breast carcinoma |
stop_gained |
2.091% (35/1674) |
2 entries |
ENSG00000085224 |
ATRX |
central nervous system primitive neuroectodermal neoplasm |
frameshift_variant |
3.602% (21/583) |
2 entries |
ENSG00000085224 |
ATRX |
oligoastrocytoma |
translational_product_function_variant |
48.21% (27/56) |
1 entry |
ENSG00000085224 |
ATRX |
astrocytoma |
stop_gained |
40.0% (6/15) |
1 entry |
ENSG00000085224 |
ATRX |
female breast carcinoma |
sequence_alteration |
3.767% (11/292) |
1 entry |
ENSG00000085224 |
ATRX |
breast ductal adenocarcinoma |
conservative_inframe_deletion |
9.948% (171/1719) |
1 entry |
ENSG00000085224 |
ATRX |
anaplastic oligodendroglioma |
frameshift_variant |
3.974% (6/151) |
2 entries |
ENSG00000085224 |
ATRX |
prostate adenocarcinoma |
frameshift_variant |
3.614% (78/2158) |
2 entries |
ENSG00000085224 |
ATRX |
squamous cell lung carcinoma |
stop_gained |
2.146% (20/932) |
1 entry |
ENSG00000085224 |
ATRX |
diffuse large B-cell lymphoma |
sequence_alteration |
0.7143% (3/420) |
1 entry |
ENSG00000085224 |
ATRX |
lung adenocarcinoma |
missense_variant |
4.551% (117/2571) |
9 entries |
ENSG00000085224 |
ATRX |
myelodysplastic syndrome |
frameshift_variant |
3.515% (29/825) |
2 entries |
ENSG00000085224 |
ATRX |
colorectal adenocarcinoma |
sequence_alteration |
6.924% (88/1271) |
2 entries |
ENSG00000085224 |
ATRX |
chronic myelomonocytic leukemia |
missense_variant |
1.778% (4/225) |
2 entries |
ENSG00000085224 |
ATRX |
Hepatoblastoma |
sequence_alteration |
13.33% (2/15) |
1 entry |
ENSG00000085224 |
ATRX |
acute lymphoblastic leukemia |
missense_variant |
0.6231% (2/321) |
2 entries |
ENSG00000085224 |
ATRX |
Breast Carcinoma by Gene Expression Profile |
missense_variant |
4.167% (4/96) |
1 entry |
ENSG00000085224 |
ATRX |
Non-Functional Pancreatic Neuroendocrine Tumor |
frameshift_variant |
22.58% (7/31) |
1 entry |
ENSG00000085224 |
ATRX |
PEComa |
frameshift_variant |
13.33% (2/15) |
1 entry |
ENSG00000085224 |
ATRX |
Adrenal Gland Neuroblastoma |
stop_gained |
6.818% (6/88) |
1 entry |
ENSG00000085224 |
ATRX |
Pineocytoma |
sequence_alteration |
33.33% (1/3) |
1 entry |
ENSG00000085224 |
ATRX |
diffuse gastric adenocarcinoma |
missense_variant |
1.22% (1/82) |
1 entry |
ENSG00000085224 |
ATRX |
Pancreatic Acinar Cell Carcinoma |
missense_variant |
2.941% (1/34) |
1 entry |
ENSG00000085224 |
ATRX |
Non-Functional Pancreatic Neuroendocrine Tumor |
stop_gained |
22.58% (7/31) |
1 entry |
ENSG00000085224 |
ATRX |
kidney Wilms tumor |
sequence_alteration |
0.303% (1/330) |
1 entry |
ENSG00000085224 |
ATRX |
Thymic Small Cell Carcinoma |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000085224 |
ATRX |
laryngeal squamous cell carcinoma |
missense_variant |
2.439% (1/41) |
1 entry |
ENSG00000085224 |
ATRX |
urothelial carcinoma |
stop_gained |
9.302% (8/86) |
1 entry |
ENSG00000085224 |
ATRX |
soft tissue sarcoma |
missense_variant |
1.02% (3/294) |
1 entry |
ENSG00000085224 |
ATRX |
urothelial carcinoma |
frameshift_variant |
9.302% (8/86) |
1 entry |
ENSG00000085224 |
ATRX |
astrocytoma |
sequence_alteration |
40.0% (6/15) |
1 entry |
ENSG00000085224 |
ATRX |
chondrosarcoma |
frameshift_variant |
7.692% (1/13) |
1 entry |
ENSG00000085224 |
ATRX |
PEComa |
stop_gained |
13.33% (2/15) |
1 entry |
ENSG00000085224 |
ATRX |
Ampulla of Vater Carcinoma |
frameshift_variant |
1.176% (1/85) |
1 entry |
ENSG00000085224 |
ATRX |
Peritoneal Well Differentiated Papillary Mesothelioma |
missense_variant |
10.0% (1/10) |
1 entry |
ENSG00000085224 |
ATRX |
bronchoalveolar adenocarcinoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000085224 |
ATRX |
mixed neuronal-glial tumor |
stop_gained |
11.11% (1/9) |
1 entry |
ENSG00000085224 |
ATRX |
prostate adenocarcinoma |
stop_gained |
3.614% (78/2158) |
1 entry |
ENSG00000085224 |
ATRX |
salivary gland carcinoma |
frameshift_variant |
3.03% (1/33) |
1 entry |
ENSG00000085224 |
ATRX |
nasal cavity and paranasal sinus carcinoma |
missense_variant |
8.696% (2/23) |
1 entry |
ENSG00000085224 |
ATRX |
pleomorphic liposarcoma |
stop_gained |
44.44% (4/9) |
1 entry |
ENSG00000085224 |
ATRX |
Ovarian Small Cell Carcinoma |
sequence_alteration |
6.667% (1/15) |
1 entry |
ENSG00000085224 |
ATRX |
Cervical Clear Cell Adenocarcinoma |
stop_gained |
100.0% (1/1) |
1 entry |
ENSG00000085224 |
ATRX |
Mantle cell lymphoma |
missense_variant |
1.493% (1/67) |
1 entry |
ENSG00000085224 |
ATRX |
Gastric Neuroendocrine Tumor G1 |
frameshift_variant |
9.091% (1/11) |
1 entry |
ENSG00000085224 |
ATRX |
papillary thyroid carcinoma |
frameshift_variant |
1.174% (6/511) |
1 entry |
ENSG00000085224 |
ATRX |
angiosarcoma |
stop_gained |
4.167% (2/48) |
1 entry |
ENSG00000085224 |
ATRX |
astrocytoma |
conservative_inframe_deletion |
40.0% (6/15) |
1 entry |
ENSG00000085224 |
ATRX |
Dysplasia in Ulcerative Colitis |
stop_gained |
12.5% (1/8) |
1 entry |
ENSG00000085224 |
ATRX |
mucosal melanoma |
missense_variant |
15.71% (11/70) |
1 entry |
ENSG00000085224 |
ATRX |
head and neck squamous cell carcinoma |
missense_variant |
0.4005% (3/749) |
1 entry |
ENSG00000085224 |
ATRX |
colon carcinoma |
conservative_inframe_deletion |
12.5% (1/8) |
1 entry |
ENSG00000085224 |
ATRX |
Vaginal Squamous Cell Carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000085224 |
ATRX |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
0.7576% (2/264) |
1 entry |
ENSG00000085224 |
ATRX |
undifferentiated pleomorphic sarcoma |
sequence_alteration |
14.52% (9/62) |
1 entry |
ENSG00000085224 |
ATRX |
Non-Functional Pancreatic Neuroendocrine Tumor |
sequence_alteration |
22.58% (7/31) |
1 entry |
ENSG00000085224 |
ATRX |
ovarian clear cell adenocarcinoma |
missense_variant |
3.03% (1/33) |
1 entry |
ENSG00000085224 |
ATRX |
Mediastinal Neuroblastoma |
missense_variant |
20.0% (1/5) |
1 entry |
ENSG00000085224 |
ATRX |
female breast carcinoma |
frameshift_variant |
3.767% (11/292) |
1 entry |
ENSG00000085224 |
ATRX |
ulcerative colitis |
missense_variant |
44.44% (4/9) |
1 entry |
ENSG00000085224 |
ATRX |
lobular breast carcinoma |
stop_gained |
5.435% (15/276) |
1 entry |
ENSG00000085224 |
ATRX |
neoplasm of mature B-cells |
missense_variant |
1.538% (1/65) |
1 entry |
ENSG00000085224 |
ATRX |
undifferentiated pleomorphic sarcoma |
conservative_inframe_deletion |
14.52% (9/62) |
1 entry |
ENSG00000085224 |
ATRX |
brain glioma |
frameshift_variant |
13.95% (6/43) |
1 entry |
ENSG00000085224 |
ATRX |
mesenchymal chondrosarcoma |
stop_gained |
33.33% (1/3) |
1 entry |
ENSG00000085224 |
ATRX |
nasal cavity and paranasal sinus carcinoma |
stop_gained |
8.696% (2/23) |
1 entry |
ENSG00000085224 |
ATRX |
undifferentiated pleomorphic sarcoma |
missense_variant |
14.52% (9/62) |
1 entry |
ENSG00000085224 |
ATRX |
oligodendroglioma |
stop_gained |
25.0% (1/4) |
1 entry |
ENSG00000085224 |
ATRX |
Adrenal Gland Neuroblastoma |
sequence_alteration |
6.818% (6/88) |
1 entry |
ENSG00000085224 |
ATRX |
Anal Squamous Cell Carcinoma |
missense_variant |
1.205% (1/83) |
1 entry |
ENSG00000085224 |
ATRX |
rhabdomyosarcoma |
sequence_alteration |
2.778% (1/36) |
1 entry |
ENSG00000085224 |
ATRX |
Parotid Gland Adenoid Cystic Carcinoma |
missense_variant |
7.692% (1/13) |
1 entry |
ENSG00000085224 |
ATRX |
choroid plexus carcinoma |
missense_variant |
20.0% (1/5) |
1 entry |
ENSG00000085224 |
ATRX |
Gastrointestinal stromal tumor |
missense_variant |
0.6579% (1/152) |
1 entry |
ENSG00000085224 |
ATRX |
head and neck squamous cell carcinoma |
conservative_inframe_deletion |
0.4005% (3/749) |
1 entry |
ENSG00000085224 |
ATRX |
adrenal gland pheochromocytoma |
frameshift_variant |
3.136% (9/287) |
1 entry |
ENSG00000085224 |
ATRX |
bone osteosarcoma |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000085224 |
ATRX |
chromophobe renal cell carcinoma |
missense_variant |
0.6757% (1/148) |
1 entry |
ENSG00000085224 |
ATRX |
extra-adrenal sympathetic paraganglioma |
stop_gained |
50.0% (1/2) |
1 entry |
ENSG00000085224 |
ATRX |
Benign Adrenal Gland Pheochromocytoma |
frameshift_variant |
3.636% (2/55) |
1 entry |
ENSG00000085224 |
ATRX |
skin melanoma |
sequence_alteration |
4.217% (49/1162) |
1 entry |
ENSG00000085224 |
ATRX |
basal cell carcinoma |
sequence_alteration |
14.71% (10/68) |
1 entry |
ENSG00000085224 |
ATRX |
Spinal Cord Astrocytoma |
stop_gained |
25.0% (1/4) |
1 entry |
ENSG00000085224 |
ATRX |
Duodenal Adenocarcinoma |
missense_variant |
5.882% (1/17) |
1 entry |
ENSG00000085224 |
ATRX |
B-cell acute lymphoblastic leukemia |
stop_gained |
0.8929% (1/112) |
1 entry |
ENSG00000085224 |
ATRX |
Bladder Adenocarcinoma |
frameshift_variant |
14.29% (1/7) |
1 entry |
ENSG00000085224 |
ATRX |
soft tissue sarcoma |
frameshift_variant |
1.02% (3/294) |
1 entry |
ENSG00000085224 |
ATRX |
Merkel cell skin cancer |
sequence_alteration |
4.211% (4/95) |
1 entry |
ENSG00000085224 |
ATRX |
gastric adenocarcinoma |
frameshift_variant |
2.973% (25/841) |
1 entry |
ENSG00000085224 |
ATRX |
Conjunctival Melanoma |
stop_gained |
25.0% (1/4) |
1 entry |
ENSG00000085224 |
ATRX |
Vulvar Squamous Cell Carcinoma |
stop_gained |
5.263% (1/19) |
1 entry |
ENSG00000085224 |
ATRX |
skin melanoma |
frameshift_variant |
4.217% (49/1162) |
1 entry |
ENSG00000085224 |
ATRX |
follicular thyroid carcinoma |
missense_variant |
1.429% (1/70) |
1 entry |
ENSG00000085224 |
ATRX |
angiosarcoma |
frameshift_variant |
4.167% (2/48) |
1 entry |
ENSG00000085224 |
ATRX |
adrenal cortex carcinoma |
conservative_inframe_deletion |
3.67% (8/218) |
1 entry |
ENSG00000085224 |
ATRX |
hepatocellular carcinoma |
frameshift_variant |
1.763% (18/1021) |
1 entry |
ENSG00000085224 |
ATRX |
renal carcinoma |
missense_variant |
5.0% (1/20) |
1 entry |
ENSG00000085224 |
ATRX |
head and neck squamous cell carcinoma |
sequence_alteration |
0.4005% (3/749) |
1 entry |
ENSG00000085224 |
ATRX |
renal cell carcinoma |
missense_variant |
1.471% (1/68) |
1 entry |
ENSG00000085224 |
ATRX |
ovarian serous adenocarcinoma |
stop_gained |
0.949% (8/843) |
1 entry |
ENSG00000085224 |
ATRX |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
sequence_alteration |
0.7576% (2/264) |
1 entry |
ENSG00000085224 |
ATRX |
Benign Adrenal Gland Pheochromocytoma |
sequence_alteration |
3.636% (2/55) |
1 entry |
ENSG00000085224 |
ATRX |
mucosal melanoma |
sequence_alteration |
15.71% (11/70) |
1 entry |
ENSG00000085224 |
ATRX |
osteosarcoma |
sequence_alteration |
6.369% (10/157) |
1 entry |
ENSG00000085224 |
ATRX |
adrenal cortex carcinoma |
missense_variant |
3.67% (8/218) |
1 entry |
ENSG00000085224 |
ATRX |
adrenal cortex carcinoma |
frameshift_variant |
3.67% (8/218) |
1 entry |
ENSG00000085224 |
ATRX |
lung PEComa |
stop_gained |
100.0% (1/1) |
1 entry |
ENSG00000085224 |
ATRX |
ovarian serous adenocarcinoma |
frameshift_variant |
0.949% (8/843) |
1 entry |
ENSG00000085224 |
ATRX |
melanoma |
stop_gained |
13.01% (19/146) |
1 entry |
ENSG00000085224 |
ATRX |
Brain Stem Glioblastoma |
frameshift_variant |
8.571% (6/70) |
1 entry |
ENSG00000085224 |
ATRX |
oral squamous cell carcinoma |
sequence_alteration |
2.29% (6/262) |
1 entry |
ENSG00000085224 |
ATRX |
Cervical Small Cell Carcinoma |
stop_gained |
50.0% (4/8) |
1 entry |
ENSG00000085224 |
ATRX |
Appendix Adenocarcinoma |
missense_variant |
1.351% (1/74) |
1 entry |
ENSG00000085224 |
ATRX |
anaplastic oligodendroglioma |
sequence_alteration |
3.974% (6/151) |
1 entry |
ENSG00000085224 |
ATRX |
soft tissue sarcoma |
stop_gained |
1.02% (3/294) |
1 entry |
ENSG00000085224 |
ATRX |
melanoma |
sequence_alteration |
13.01% (19/146) |
1 entry |
ENSG00000085224 |
ATRX |
adrenocortical adenoma |
stop_gained |
2.439% (1/41) |
1 entry |
ENSG00000085224 |
ATRX |
pleomorphic liposarcoma |
missense_variant |
44.44% (4/9) |
1 entry |
ENSG00000085224 |
ATRX |
primary peritoneal carcinoma (disease) |
frameshift_variant |
100.0% (1/1) |
1 entry |
ENSG00000085224 |
ATRX |
meningioma (disease) |
missense_variant |
1.37% (1/73) |
1 entry |
ENSG00000085224 |
ATRX |
adrenal cortex carcinoma |
sequence_alteration |
3.67% (8/218) |
1 entry |
ENSG00000085224 |
ATRX |
pharyngeal squamous cell carcinoma |
missense_variant |
0.6993% (1/143) |
1 entry |
ENSG00000085224 |
ATRX |
rectal adenocarcinoma |
sequence_alteration |
2.559% (14/547) |
1 entry |